Canada's Sunnybrook Health Sciences Centre Joins Elekta and Philips Research
Consortium on MRI-Guided Radiation Therapy
Research projects to have implications for cancer treatment worldwide
TORONTO, May 10, 2013 /CNW/ - Elekta (NSE: EKTAb) and Royal Philips
Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health
Sciences Centre (Toronto, Canada) will join their growing consortium to
validate the clinical potential of MRI-guided radiation therapy.
Sunnybrook Health Sciences Centre, the sixth largest cancer center in North
America, is the fourth member to sign the research agreement to evaluate the
new technology, which merges radiation therapy and magnetic resonance imaging
(MRI) in a single system. Current clinical members of the group include the
University Medical Center Utrecht, The University of Texas MD Anderson Cancer
Center, and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.
Integrating an advanced 1.5 Tesla MRI machine with a sophisticated radiation
therapy system will provide physicians with exceptional depictions of a
patient's soft tissues and tumor and allow them to dynamically track their
motion. This breakthrough innovation is designed to permit doctors to deliver
radiation in real time under MR guidance for the most precise cancer
"Sunnybrook Health Sciences Centre distinguishes itself in the world of
science and medicine by its longstanding dedication of integrating research
into clinical domain for the benefit of patients," says Tomas Puusepp, Elekta
President and CEO. "With their international strength in the physical sciences
– particularly in imaging technology – and its worldwide repute as a top
flight cancer center, Sunnybrook is an ideal partner to help us advance this
According to Michael Julius, Vice President, Research at Sunnybrook Health
Sciences Centre, Sunnybrook's participation in the research consortium will
bring a unique team of physicists, engineers and clinicians to focus on
validating the advantages of MRI-guided radiation therapy through technology
development and clinical trials.
"We have identified a number of areas to study the value of this technology
for patients," he says. "The ultimate goal – acquiring high resolution MRI
images of pathology in real time as the radiation is being delivered – could
have a dramatic impact on patient health and clinical outcomes."
Today, the safety margin of normal tissue around the tumor absorbs a large
portion of the radiation beam, adds Jean-Philippe Pignol, Professor of
Radiation Oncology and a key leader on the Elekta partnership at Sunnybrook's
Odette Cancer Centre. "The expectation is that MR-guided radiation therapy
will enable us to treat more cancer tissue than normal tissue. In doing so, we
could apply, in a single fraction, a huge dose to the tumor while avoiding
side effects to normal tissues," he says.
"The development of advanced imaging solutions for oncology therapy planning
and delivery is a key focus area for Philips," says Gene Saragnese, CEO
Imaging Systems at Philips Healthcare. "Philips is already closely working
together with Sunnybrook Health Sciences Centre in this field, and we welcome
their expertise to the research consortium for MR guided radiotherapy. The
members will jointly work on the design and implementation of the clinical
studies with the objective of bringing image-guided oncology therapy to the
next level, and ultimately creating the future of healthcare."
The integrated MRI-guided radiation therapy system is in development and not
available for sale.
For further information, please contact: Johan Andersson, Director, Investor
Relations, Elekta AB Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management,
Elekta Tel: +1 770-670-2447, email: email@example.com Time zone:
ET: Eastern Time
Steve Klink, Philips Corporate Communications Tel: +31 20 5977415, email:
About Elekta Elekta is a human care company pioneering significant
innovations and clinical solutions for treating cancer and brain disorders.
The company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and brachytherapy, as
well as workflow enhancing software systems across the spectrum of cancer
care. Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to both
healthcare providers and patients, Elekta aims to improve, prolong and even
save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
About Royal Philips Electronics Royal Philips Electronics (NYSE: PHG, AEX:
PHIA) is a diversified health and well-being company, focused on improving
people's lives through meaningful innovation in the areas of Healthcare,
Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips
posted 2012 sales of EUR 24.8 billion and employs approximately 116,000
employees with sales and services in more than 100 countries. The company is a
leader in cardiac care, acute care and home healthcare, energy efficient
lighting solutions and new lighting applications, as well as male shaving and
grooming and oral healthcare. News from Philips is located at
To view this news release in HTML formatting, please use the following URL:
CO: Sunnybrook Health Sciences Centre
NI: HEA MTC BTC
-0- May/10/2013 13:13 GMT
Press spacebar to pause and continue. Press esc to stop.